CollPlant Biotechnologies

Expanding Distribution And Pipeline Advances Will Open New Markets

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

27 Apr 25

Updated

01 May 25

Views

n/a

AnalystConsensusTarget's Fair Value

n/a

-55.4%

-16.0%

-55.4%

-16.0%

You can edit this narrative until May 12 5:59 AM. Then, changes will post as Updates.

Author's Valuation

US$11.5686.9% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates1

Shared on 01 May 25

Fair value Decreased 3.67%

AnalystConsensusTarget Fair Value

US$11.56

86.9% undervalued

Future estimation in

Growth p.a.

Decrease

Increase

Current revenue growth rate

40.62%

Biotech revenue growth rate

9.62%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

9.00%

Calculation

US$2.90m

Earnings '28

88.19x

PE Ratio '28

US$255.72m

Market Cap '28

US$255.72m

Market Cap '28

17.40m

No. shares '28

US$14.70

Share Price '28

US$14.70 Share Price '28

Discounted to 2025 @ 8.34% p.a.

US$11.56

Fair Value '25